Collectively, these findings highlight the promise of a dual-spanlastic-based delivery platform as a safe, non-invasive, and effective therapeutic strategy for glaucoma, combining IOP-lowering efficacy with targeted caspase-2 silencing in RGC. Here, CASP2 is linked to glaucoma.